UroGen Pharma Ltd.

NasdaqGM URGN

UroGen Pharma Ltd. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -129.11%

UroGen Pharma Ltd. Net Income Margin is -129.11% for the Trailing 12 Months (TTM) ending September 30, 2024, a 4.50% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

UroGen Pharma Ltd. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -135.20%, a 22.81% change year over year.
UroGen Pharma Ltd. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -175.16%, a 38.20% change year over year.
UroGen Pharma Ltd. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -283.41%, a 92.07% change year over year.
UroGen Pharma Ltd. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -3,572.42%, a 99.28% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGM: URGN

UroGen Pharma Ltd.

CEO	Ms. Elizabeth A. Barrett
IPO Date	May 4, 2017
Location	United States
Headquarters	400 Alexander Park
Employees	217
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals Plastics

Description

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Key trends

Past 5 years